Chronic Venous Disease and Cardiovascular Risk: Potential benefits of venoactive medications

This Vein and Lymphatic University Grand Rounds session, moderated by Dr. Manjit Gohel (UK), features discussants Dr. Liza Ochoa (Mexico) and Dr. Malay Patel (India), and a keynote presentation by Dr. Alejandro González (Mexico). The session explores the complex relationship between chronic venous disease (CVD) and cardiovascular risk, reviewing shared pathophysiology, severity‑based associations, population‑level evidence, and the emerging role of endothelial glycocalyx injury. The program includes clinical data analysis, international perspectives, and practical considerations for risk assessment and patient counseling. Key learning points: • Chronic venous disease and cardiovascular disease share endothelial-based mechanisms, particularly glycocalyx injury, which promotes inflammation and alters vascular homeostasis. • Increasing CEAP classification correlates with elevated risk of major adverse cardiovascular events in multiple large population datasets. • Observational studies suggest associations between CVD and atrial fibrillation, heart failure, and increased all‑cause mortality, though causality has not been established. • Venoactive medications with endothelial effects, such as sulodexide, show potential benefit in reducing inflammatory markers, but prospective data specific to CVD‑related cardiovascular risk are lacking. • Integrating cardiovascular risk screening into venous practice may improve holistic patient care, particularly in individuals with advanced disease stages. This session provides clinically grounded insights to support evidence‑based decision‑making in patients with complex venous and cardiovascular risk profiles.